Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

E 3810

Known as: E-3810, E3810 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Tumor angiogenesis is a degenerate process regulated by a complex network of proangiogenic factors. Existing antiangiogenic drugs… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
1998
Highly Cited
1998
Rabeprazole (LY307640, E3810) is a new, potent, proton pump inhibitor. A single daily 20 mg dose significantly decreases 24‐h… Expand
1997
1997
1. Induction of endogenous cytochrome P4501A1 (CYP1A1) by benzimidazole derivatives has been investigated in the human hepatoma… Expand
Highly Cited
1995
Highly Cited
1995
To compare the interaction potential of E3810, [(±)‐sodium 2‐[[4‐(3‐methoxypropoxy)‐3‐methylpyridin‐2‐yl]methylsulfinyl]‐1H… Expand
Review
1995
Review
1995
Inhibition of the gastric proton pump is gaining acceptance as the treatment of choice for severe gastrooesophageal reflux… Expand
Highly Cited
1995
Highly Cited
1995
We studied the kinetic disposition and metabolism of E3810 [(±)‐sodium 2‐[[4‐(3‐methoxypropoxy)‐3‐methylpyridin‐2‐yl… Expand
Highly Cited
1994
Highly Cited
1994
E3810 is a new H+,K(+)-ATPase inhibitor with a substituted benzimidazole, which is under clinical investigation for peptic ulcer… Expand
1993
1993
Omeprazole and E3810 were found to inhibit gastric H+,K(+)-ATPase following different biochemical mechanisms. Effects of the… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Highly Cited
1991
Highly Cited
1991
A substituted benzimidazole ([4-(3-methoxypropoxy)-3-methylpyridine-2-yl]methylsulfinyl)- 1H-benzimidazole sodium salt (E3810… Expand
Highly Cited
1990
Highly Cited
1990
The half maximal inhibitory concentrations (IC50) of substituted benzimidazoles for the H+, K(+)-ATPase in hog gastric vesicles… Expand